SEC FORM 4 SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
 
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
POLK DENNIS

(Last) (First) (Middle)
44201 NOBEL DRIVE

(Street)
FREMONT CA 94538

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Concentrix Corp [ CNXC ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
12/01/2020
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 12/01/2020 J(1) 43,966 A $0 43,966 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Employee Stock Option (Right to Buy) $61.83(2) 12/01/2020 J(2) 10,584 12/01/2020 10/03/2023 Common Stock 10,584 $0 10,584 D
Employee Stock Option (Right to Buy) $62.9(2) 12/01/2020 J(2) 15,514 12/01/2020 10/07/2024 Common Stock 15,514 $0 15,514 D
Employee Stock Option (Right to Buy) $89.21(2) 12/01/2020 J(2) 11,235 12/01/2020 10/06/2025 Common Stock 11,235 $0 11,235 D
Employee Stock Option (Right to Buy) $112.08(2) 12/01/2020 J(2) 13,778 (3) 10/04/2026 Common Stock 13,778 $0 13,778 D
Employee Stock Option (Right to Buy) $128.67(2) 12/01/2020 J(2) 12,188 (4) 10/03/2027 Common Stock 12,188 $0 12,188 D
Employee Stock Option (Right to Buy) $96.46(2) 12/01/2020 J(2) 37,851 (5) 04/09/2028 Common Stock 37,851 $0 37,851 D
Employee Stock Option (Right to Buy) $76.01(2) 12/01/2020 J(2) 71,003 (6) 10/11/2028 Common Stock 71,003 $0 71,003 D
Employee Stock Option (Right to Buy) $110.44(2) 12/01/2020 J(2) 46,588 (7) 10/02/2029 Common Stock 46,588 $0 46,588 D
Explanation of Responses:
1. In connection with the spin-off of Concentrix Corporation ("Concentrix") by SYNNEX Corporation ("SYNNEX"), on December 1, 2020, SYNNEX distributed all of the issued and outstanding shares of Concentrix common stock to SYNNEX stockholders (the "Distribution"). SYNNEX stockholders received one share of Concentrix common stock for each share of SYNNEX common stock held as of the close of business on November 17, 2020. The number of shares of Concentrix common stock reported as acquired on this Form 4 reflects the number of shares of Concentrix common stock, including shares of restricted stock, acquired by the reporting person pursuant to the Distribution.
2. In connection with the spin-off of Concentrix by SYNNEX and pursuant to the employee matters agreement between SYNNEX and Concentrix, on December 1, 2020, each outstanding option to purchase SYNNEX common stock was converted into a stock option to purchase SYNNEX common stock and a stock option to purchase Concentrix common stock, in each case with respect to the same number of shares as the original SYNNEX stock option. The exercise price of the converted Concentrix stock option cannot yet be determined and will be adjusted in accordance with the terms of the employee matters agreement. The exercise price set forth on this Form 4 reflects the exercise price of the original SYNNEX stock option and will be updated by amendment of this Form 4 once the adjusted exercise price is known.
3. The converted Concentrix stock option has the same vesting schedule as the original SYNNEX stock option, which vested as to 20% of the shares on October 4, 2017, the first anniversary of the date of grant, and vests as to 1/60th of the shares monthly thereafter.
4. The converted Concentrix stock option has the same vesting schedule as the original SYNNEX stock option, which vested as to 20% of the shares on October 3, 2018, the first anniversary of the date of grant, and vests as to 1/60th of the shares monthly thereafter.
5. The converted Concentrix stock option has the same vesting schedule as the original SYNNEX stock option, which vested as to 20% of the shares on October 3, 2018 and vests as to 1/60th of the shares monthly thereafter.
6. The converted Concentrix stock option has the same vesting schedule as the original SYNNEX stock option, which vested as to 20% of the shares on October 11, 2019, the first anniversary of the date of grant, and vests as to 1/60th of the shares monthly thereafter.
7. The converted Concentrix stock option has the same vesting schedule as the original SYNNEX stock option, which vested as to 20% of the shares on October 2, 2020, the first anniversary of the date of grant, and vests as to 1/60th of the shares monthly thereafter.
Remarks:
/s/ Andrew A. Farwig, Attorney-in-Fact 12/03/2020
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.